Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial
…, Y Yanagita, R Nishimura, H Iwase, S Kamigaki… - The lancet …, 2012 - thelancet.com
Background Aromatase inhibitors have shown increased efficacy compared with tamoxifen
in postmenopausal early breast cancer. We aimed to assess the efficacy and safety of …
in postmenopausal early breast cancer. We aimed to assess the efficacy and safety of …
Clinical significance of the 21‐gene signature (Oncotype DX) in hormone receptor‐positive early stage primary breast cancer in the Japanese population
…, T Nakayama, M Kashiwaba, S Kamigaki… - Cancer, 2010 - Wiley Online Library
BACKGROUND: The 21‐gene signature has been intensively studied and incorporated into
major guidelines for treatment decision in early breast caner. However, it remains to be …
major guidelines for treatment decision in early breast caner. However, it remains to be …
The difference in prognostic outcomes between de novo stage IV and recurrent metastatic patients with hormone receptor-positive, HER2-negative breast cancer
JUN Yamamura, S Kamigaki, J Fujita, H Osato… - in vivo, 2018 - iv.iiarjournals.org
Background/Aim: Patients with de novo stage IV and recurrent metastatic breast cancer are
often treated with the same strategies, although the difference in prognostic outcomes …
often treated with the same strategies, although the difference in prognostic outcomes …
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese …
…, H Iwata, M Kashiwaba, Y Fujiwara, S Kamigaki… - Breast cancer research …, 2011 - Springer
Despite extensive evaluation of first-line bevacizumab-containing therapy in randomized
trials in locally recurrent/metastatic breast cancer (LR/mBC), data from Japanese populations …
trials in locally recurrent/metastatic breast cancer (LR/mBC), data from Japanese populations …
[HTML][HTML] Differential involvement of autophagy and apoptosis in response to chemoendocrine and endocrine therapy in breast cancer: JBCRG-07TR
T Ueno, N Masuda, S Kamigaki, T Morimoto… - International journal of …, 2019 - mdpi.com
Endocrine therapy is an essential component in the curative treatment of hormone receptor (HR)-positive
breast cancer. To improve treatment efficacy, the addition of metronomic …
breast cancer. To improve treatment efficacy, the addition of metronomic …
Analysis of Ki‐67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer
…, Y Yanagita, R Nishimura, H Iwase, S Kamigaki… - Cancer, 2013 - Wiley Online Library
BACKGROUND: The increasing costs associated with large‐scale adjuvant trials mean that
the prognostic value of biologic markers is increasingly important. The expression of nuclear …
the prognostic value of biologic markers is increasingly important. The expression of nuclear …
Down-Regulation of Intratumoral Aromatase Messenger RNA Levels by Docetaxel in Human Breast Cancers
Y Miyoshi, SJ Kim, K Akazawa, S Kamigaki, S Ueda… - Clinical cancer …, 2004 - AACR
Purpose: The reason why chemotherapy induces resistance to subsequent hormonal
therapy remains to be clarified in postmenopausal breast cancers. We hypothesized that …
therapy remains to be clarified in postmenopausal breast cancers. We hypothesized that …
Response to first-line recurrence treatment influences survival in hormone receptor-positive, HER2-negative breast cancer: a multicenter study
J Yamamura, S Kamigaki, M Tsujie, J Fujita, H Osato… - in vivo, 2019 - iv.iiarjournals.org
Background/Aim: Little evidence is currently available on significant determinants of post-recurrence
survival for patients with hormone receptor-positive (HR+), HER2-negative (HER2−) …
survival for patients with hormone receptor-positive (HR+), HER2-negative (HER2−) …
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative …
K Aogi, M Yoshida, Y Sagara, S Kamigaki… - Cancer chemotherapy …, 2011 - Springer
Purpose Gemcitabine (GEM)–paclitaxel combination therapy has been confirmed as a
standard therapy for metastatic/recurrent breast cancer (MBC) in Western countries. This study …
standard therapy for metastatic/recurrent breast cancer (MBC) in Western countries. This study …
A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer …
T Ueno, N Masuda, S Kamigaki, T Morimoto… - Cancer …, 2018 - Wiley Online Library
Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to
increased breast conservation rates. To improve the clinical response, metronomic …
increased breast conservation rates. To improve the clinical response, metronomic …